A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.
about
Mechanisms of drug resistance in kinases.Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism.Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approachThe Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study.Molecular mechanisms of drug resistance in tyrosine kinases cAbl and cKit.Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies.Opening the door to the development of novel Abl kinase inhibitors.Molecular modeling study of the induced-fit effect on kinase inhibition: the case of fibroblast growth factor receptor 3 (FGFR3).Development of 'DFG-out' inhibitors of gatekeeper mutant kinases.An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit.Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement.Synthesis and identification of GZD856 as an orally bioavailable Bcr-AblT315I inhibitor overcoming acquired imatinib resistance.Identification of common inhibitors of wild-type and T315I mutant of BCR-ABL through the parallel structure-based virtual screening.
P2860
Q27692567-94107A2F-4E40-45A3-B0DF-5EA799C5243AQ34491764-F92BFB57-9B26-403E-93A1-246B44E57200Q35592751-3A5568C4-7906-4930-B7E7-B458F3717516Q35752926-94DAACF1-5C5F-4619-B76C-4BA276EDCF5CQ37871600-A95E9EA7-FC5B-45D0-A3A5-ED8548420F71Q38261599-BCE31ED7-618D-4D0D-9A55-94964FA92E82Q38806783-3ECADBE6-A343-4371-A01F-0166932ABEEDQ39025426-67B03F7A-7E2D-453D-926D-7B5264F72982Q39310783-B2989A90-5124-4D89-A729-065590E23773Q39326425-E46F0099-6236-46BD-B4EC-CF84561F2370Q47700032-3A40B103-CEE5-4D63-8CAE-6BD2D730707BQ47959367-86D7862B-B0F8-40C2-B489-AC02A6791D45Q53365053-90D01A56-FB6B-492A-80CF-2BDCF0C53288
P2860
A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
A type-II kinase inhibitor cap ...... gatekeeper" mutant of Bcr-Abl.
@ast
A type-II kinase inhibitor cap ...... gatekeeper" mutant of Bcr-Abl.
@en
A type-II kinase inhibitor cap ...... gatekeeper" mutant of Bcr-Abl.
@nl
type
label
A type-II kinase inhibitor cap ...... gatekeeper" mutant of Bcr-Abl.
@ast
A type-II kinase inhibitor cap ...... gatekeeper" mutant of Bcr-Abl.
@en
A type-II kinase inhibitor cap ...... gatekeeper" mutant of Bcr-Abl.
@nl
prefLabel
A type-II kinase inhibitor cap ...... gatekeeper" mutant of Bcr-Abl.
@ast
A type-II kinase inhibitor cap ...... gatekeeper" mutant of Bcr-Abl.
@en
A type-II kinase inhibitor cap ...... gatekeeper" mutant of Bcr-Abl.
@nl
P2093
P2860
P356
P1476
A type-II kinase inhibitor cap ...... gatekeeper" mutant of Bcr-Abl.
@en
P2093
Fangxian Sun
Francisco Adrian
Guobao Zhang
Hwan Geun Choi
Hyun Soo Lee
Jianming Zhang
Jürgen Mestan
Markus Warmuth
Nathanael S Gray
Paul W Manley
P2860
P304
P356
10.1021/JM901808W
P407
P577
2010-08-01T00:00:00Z